95 Results for "

Dual inhibition

" in MedChemExpress (MCE) Product Catalog:
Products (95)

95 Results for "Dual inhibition" in MCE Product Catalog:

  • Targets Recommended:
89
89 Publications Verification
Cat. No.: HY-50878A
CAS No.: 1415560-69-8
Synonyms: PF-02341066 hydrochloride
Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-108347
CAS No.: 142715-48-8
Purity:  99.19%
Target:  

P-glycoprotein BCRP

Research Areas:  

Metabolic Disease

CP-100356 hydrochloride is an orally active dual MDR1 (P-gp)/BCRP inhibitor, with an IC50s of 0.5 and 1.5 µM for inhibiting MDR1-mediated Calcein-AM transport and BCRP-mediated Prazosin transport, respectively. CP-100356 hydrochloride is also a weak inhibitor of OATP1B1 (IC50=∼66 µM). CP-100356 hydrochloride is devoid of inhibition against MRP2 and major human P450 enzymes (IC50>15 µM) .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-104042
CAS No.: 1644545-52-7
Purity:  99.87%
Synonyms: AG-881
Research Areas:  

Cancer

Vorasidenib (AG-881) is an orally available, brain penetrant second-generation dual mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2) inhibitor. Vorasidenib (AG-881) exhibits nanomolar inhibition of (D)-2-hydroxyglutarate (D-2-HG), and the IC50 ranges of 0.04~22 nM against IDH1 R132C, IDH1 R132G, IDH1 R132H and IDH1 R132S and 7~14 nM against IDH2 R140Q and 130 nM against IDH2 R172K. Vorasidenib can be used for the study of grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1/2 mutation .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-12299
CAS No.: 837422-57-8
Purity:  99.87%
Synonyms: Dual LCK/SRC inhibitor
Target:  

Src

Research Areas:  

Cancer

WH-4-023 is a potent and selective dual Lck/Src inhibitor with IC50 of 2 nM/6 nM for Lck and Src kinase respectively; little inhibition on p38α and KDR.
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-103160A
CAS No.: 58337-38-5
Purity:  99.67%
EHNA hydrochloride is a potent and selective dual inhibitor of cyclic nucleotide phosphodiesterase 2 (PDE2)(IC50=4 μM) and adenosine deaminase (ADA). EHNA hydrochloride exerts a concentration inhibition of the cGMP-stimulated PDE II (cGs-PDE)(IC50:0.8 μM (human), 2 μM (porcine myocardium)), but has smaller inhibitory effect on the unstimulated PDE2 activity. EHNA hydrochloride play roles in mediating diverse pharmacological responses, including antiviral, antitumour and antiarrhythmic effects .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-15838
CAS No.: 147591-46-6
Purity:  99.92%
Target:  

DYRK

Research Areas:  

Cancer

ID-8 is an inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase (DYRK). ID-8 sustains embryonic stem cell (ESC) self-renewal and pluripotency. ID-8 enhances Wnt-mediated hESC survival and proliferation via inhibition of DYRKs .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-N6712
CAS No.: 87-11-6
Synonyms: Acetopyrrothin
Thiolutin (Acetopyrrothin) is a sulfur-containing antibiotic, which is a potent inhibitor of bacterial and yeast RNA polymerases. Thiolutin can be produced by Streptomyces. Thiolutin inhibits AMSH (IC50 = 4 μM) and Rpn11 (IC50 = 0.53 μM). Thiolutin is a dual inhibitor of BRCC36 and the NLRP3 inflammasome, exhibiting anti-inflammatory effects. Thiolutin effectively suppresses the interaction between BRCC36 and HMGCR, leading to the inhibition of HCC growth. Thiolutin attenuates pyroptosis and NLRP3 inflammasome activation. Thiolutin markedly alleviates renal injury and inflammatory process in IgAN. Thiolutin is an anti-angiogenic compound which can ease Doxorubicin-induced cardiotoxicity (DOXIC) [1][2][3][4][5].
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-U00177
CAS No.: 501698-03-9
Target:  

Survivin

Research Areas:  

Cancer

GDP366, a dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells.
loading...
    loading...
Cat. No.: HY-144315
CAS No.: 2415281-52-4
Purity:  99.76%
Synonyms: Snail/HDAC-IN-1
Target:  

HDAC

Research Areas:  

Cancer

CYD19 is a potent Snail/HDAC dual target inhibitor. CYD19 displays potent inhibitory activity against HDAC1 with an IC50 of 0.405 μM and potent inhibition against Snail with a Kd of 0.18 μM. CYD19 increases histone H4 acetylation in HCT-116 cells and decreases the expression of Snail protein to induce cell apoptosis .
loading...
    loading...
Cat. No.: HY-B2004
CAS No.: 130000-40-7
Thifluzamide is a fungicide that inhibits fungal respiration by blocking the ubiquinone-binding site in mitochondrial complex II. Thifluzamide exhibits significant activity against Basidiomycota pathogens (such as Rhizoctonia cerealis, Ustilago and Puccinia genera) and is commonly used in studies on wheat sharp eyespot. Thifluzamide displays a dual mechanism in regulating lipid metabolism: it reduces fatty acid synthase activity to inhibit endogenous fatty acid synthesis, and increases carnitine palmitoyltransferase-I activity to accelerate fatty acid β-oxidation, thereby reducing total cholesterol and triglyceride levels in the liver. Thifluzamide also induces hepatotoxicity in zebrafish models and carries a risk of developmental toxicity. Thifluzamide inhibition of Rhizoctonia cerealis may result in low to moderate levels of drug resistance, leading to the generation of stable drug-resistant mutants .
loading...
    loading...
Cat. No.: HY-172429
CAS No.: 2489185-38-6
Synonyms: ORIC-114
Target:  

EGFR

Research Areas:  

Neurological Disease Cancer

Enozertinib (ORIC-114) is an orally active, CNS-penetrant, highly selective and irreversible dual EGFR/HER2 inhibitor that exhibits potent and targeted inhibition of exon 20 insertion mutations. Enozertinib exhibits high kinome selectivity for the EGFR family of receptors to reduce off-target kinase liabilities. Enozertinib induces tumor regression and demonstrates antitumor activity in central nervous system and non-small cell lung cancer (NSCLC) tumor models. Enozertinib can be used for the research of solid tumors and NSCLC .
loading...
    loading...
Cat. No.: HY-123538
CAS No.: 24269-96-3
Purity:  98.06%
GRK2 Inhibitor 1 (methyl 5-[2-(5-nitro-2-furyl)vinyl]-2-furoate) is a dual GRK2/β-ARK1 inhibitor that induces dopamine (DA) inhibition reversal (DIR). GRK2 Inhibitor 1 can also block serotonin-induced or neurotensin-induced DIR reversal. Note: DIR refers to the phenomenon in which neurons in addiction-related brain pathways become less sensitive to DA inhibition when exposed to moderate concentrations of DA for a long time .
loading...
    loading...
Cat. No.: HY-175479
CAS No.: 3114869-49-4
GLPG4970 is a potent, selective and orally active salt-inducible kinase 2/3 (SIK2/SIK3) dual inhibitor with IC50 values of 0.3 nM and 0.7 nM. GLPG4970 has weak inhibition of hERG channel with an IC50 of 29 μM. GLPG4970 can decrease TNFα release and increase IL-10 release GLPG4970 can be used for the researches of inflammation and immunology, such as colitis .
loading...
    loading...
Cat. No.: HY-172429A
Synonyms: ORIC-114 hemihydrate
Target:  

EGFR

Research Areas:  

Neurological Disease Cancer

Enozertinib (ORIC-114) hemihydrate is an orally active, CNS-penetrant, highly selective and irreversible dual EGFR/HER2 inhibitor that exhibits potent and targeted inhibition of exon 20 insertion mutations. Enozertinib hemihydrate exhibits high kinome selectivity for the EGFR family of receptors to reduce off-target kinase liabilities. Enozertinib hemihydrate induces tumor regression and demonstrates antitumor activity in central nervous system and non-small cell lung cancer (NSCLC) tumor models. Enozertinib hemihydrate can be used for the research of solid tumors and NSCLC .
loading...
    loading...
Cat. No.: HY-112293
CAS No.: 202272-68-2
Purity:  99.54%
Target:  

EGFR

Research Areas:  

Cancer

GW2974 is a potent dual inhibitor of EGFR and HER2 with IC50 value of 0.007 μM and 0.016 μM, respectively. GW2974 demonstrates in vitro inhibition of the EGFR and HER2 and inhibits the growth of tumor cell. GW2974 can be used for glioblastoma multiforme (GBM) disease research .
loading...
    loading...
Cat. No.: HY-144627
CAS No.: 3033401-45-2
Purity:  98.01%
Target:  

PROTACs TAM Receptor Ras

Research Areas:  

Cancer

PROTAC Axl Degrader 2 is an orally active and selective AXL PROTAC degrader with dual activities of AXL kinase inhibition and AXL protein degradation. PROTAC Axl Degrader 2 induces cytoplasmic vacuolization, excessive macropinosome production, oncosis, H-Ras activation, and Rac1-dependent non-apoptotic cell death. PROTAC Axl Degrader 2 inhibits the proliferation and migration of cancer cells, and also suppresses the growth of tumor cell xenografts under in vivo conditions. PROTAC Axl Degrader 2 can be used in research related to breast cancer .
loading...
    loading...
Cat. No.: HY-178360
CAS No.: 2966791-41-1
NP1192 is a potent, selective PROTAC NAT10 degrader. NP1192 promotes NAT10 ubiquitination and degradation. NP1192 inhibits ac4C modification. NP1192 demonstrates dual inhibition of hypoxia-driven glycolysis and immunosuppression via NAT10/HIF-1α/PD-L1 axis disruption, achieving superior antitumor efficacy and synergizing with anti-PD-L1 both in vitro and in vivo. NP1192 can be used for ovarian, cervical, and glioblastoma cancer research .
loading...
    loading...
Cat. No.: HY-174366
CAS No.: 2256080-83-6
Target:  

c-Fms PI3K

Research Areas:  

Cancer

JMC14 is a selective and orally active PI3Kδ and CSF1R inhibitor with IC50 values of 12 nM and 143 nM, respectively. JMC14 preferentially inhibits PI3Kδ-mediated signaling at the cellular level. JMC14 demonstrates potent antitumor activity against B-cell lymphomas and triple-negative breast cancer (TNBC) in both in vitro and vivo studies. JMC14 can be used for the study of antitumor immunity .
loading...
    loading...
Cat. No.: HY-149819
CAS No.: 2944087-54-9
Purity:  99.60%
Target:  

HDAC CDK

Research Areas:  

Cancer

CDK/HDAC-IN-3 is an orally active HDACs/CDKs dual inhibitor. CDK/HDAC-IN-3 has potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2 and HDAC3 with IC50 values of 98.32 nM, 98.85 nM, 100 nM, 62.12 nM, 93.28nM and 82.87 nM. CDK/HDAC-IN-3 can be used for the acute myeloid leukemia (AML) .
loading...
    loading...
Cat. No.: HY-156523
CAS No.: 2478592-86-6
Purity:  99.73%
Target:  

MAP4K

Research Areas:  

Cancer

TNIK&MAP4K4-IN-1 (compound A-39) is a dual inhibitor of TNIK and MAP4K4/HGK with IC50s of 1.29 nM and <10 nM,respectively,in human hepaticstellate cell LX-2. TNIK&MAP4K4-IN-1 can be used for cancer and fibrosis inhibition .
loading...
    loading...